16+
Major trials tracked
Targeted & bispecific oncology · Live ClinicalTrials.gov data
Zanubrutinib (Brukinsa) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 zanubrutinib (Brukinsa) trials on ClinicalTrials.gov by enrolment, 5 of them actively recruiting. The next phase 3 primary completion among them is expected Jul 2028. Refreshed daily. Add up to four competitors to compare pipelines side by side.
4
Phase 3 trials
5
Actively recruiting
Jul 2028
Next phase 3 primary completion
3,227
Participants across trials
BeOne Medicines
Lead sponsor by trial count
zanubrutinib (16)13 active2017–2034
zanubrutinib
'17
'19
'21
'23
'25
'27
'29
'31
'33
zanubrutinib
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)P2
ALPINEP3
MANGROVEP3
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) TreatmentP2
ZR-CHOP in DLBCL With Specific Gene AbnormalityP2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaP2
MAHOGANYP3
ALMONDP2
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaP3
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaP2
Epco, Zanu, Ritux for R/R FL or MZLP2
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLLP2
Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCLP2
LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T FailureP2
PRAISEP2
ZEN-CLLP2
Upcoming readouts
11 ahead · zanubrutinib
Select a trial to load its full ClinicalTrials.gov record.
Key zanubrutinib trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.
Track zanubrutinib with ComplyRx
Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.
Related drug pipelines
FAQ
- How many clinical trials are running for zanubrutinib?
- ClinicalTrials.gov lists more than 16 phase 2–4 zanubrutinib trials. This page tracks the 16 largest by enrolment: 12 phase 2, 4 phase 3, and 0 phase 4 among them, with 5 actively recruiting. Updated daily.
- Are there clinical trials for Brukinsa?
- Brukinsa is the brand name for zanubrutinib, so zanubrutinib trials on ClinicalTrials.gov cover it. ClinicalTrials.gov lists more than 16 phase 2–4 zanubrutinib trials. This page tracks the 16 largest by enrolment: 12 phase 2, 4 phase 3, and 0 phase 4 among them, with 5 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare zanubrutinib against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
